Jennifer Milucky

Jennifer Milucky

Auto-generated profile, based on publicly available information

Jennifer Milucky

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta , Georgia , USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
SGShikha Garg
Shikha Garg
KPKadam Patel
Kadam Patel
HPHuong Pham
Huong Pham
MWMichael Whitaker
Michael Whitaker
AOAlissa O’halloran
Alissa O’halloran
FHFiona P. Havers
Fiona P. Havers
This study used data from a national CDC network to examine trends related to COVID-19 hospitalization, care, and clinical outcomes across the United States. Visual Clinical Trends in COVID-19 Hospitalizations. This study used data from a national CDC network to examine trends related to COVID-19 hospitalization, care, and clinical outcomes acr... Background: The COVID-19 pandemic has caused substantial morbidity and mortality. Objective: To describe monthly clinical trends among adults hospitalized with COVID-19. Design: Pooled cross-sectio...

1 February 2019 in Vaccine
Verified
Journal Article
Open access
JMJennifer Milucky
Jennifer Milucky
MCMaria de Gloria Carvalho
Maria de Gloria Carvalho
NRNadine Rouphael
Nadine Rouphael
NBNancy M. Bennett
Nancy M. Bennett
HTH.KEipp Talbot
H.KEipp Talbot
ASAnna Sharova
Anna Sharova
Vaccination of children with 13-valent pneumococcal conjugate vaccine (PCV13) led to declines in vaccine-type pneumococcal nasopharyngeal carriage among adults through indirect effects. In August 2014, PCV13 immunization of all U.S. adults ≥65 years of age was recommended. This study sought to define prevalence and serotype distribution of pneumococcal carriage among adults ≥65 years of age and to describe risk factors for colonization soon after introduction of PCV13 in adults. A cross-sectional survey of non-institutionalized U.S. adults ≥65 years of age was conducted in four states in 2015-2016. Demographic information, risk factors for disease, PCV13 vaccination history, and nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected. NP and OP swabs were processed separately and pneumococcal isolates were serotyped by Quellung reaction. Antimicrobial susceptibility of pneumococcal isolates was performed. NP swabs also underwent real-time PCR for pneumococcal detection and serotyping. Of 2989 participants, 45.3% (1354/2989) had been vaccinated with PCV13. Fifty-five (1.8%) carried pneumococcus (45 identified by culture and 10 by real-time PCR only) and PCV13 serotypes were found in eight (0.3%) participants. Almost half (22/45) of pneumococcal isolates were not susceptible to at least one of the antibiotics tested. Vaccine-type carriage among vaccinated and unvaccinated individuals was similar (0.2% vs. 0.1%, respectively). Respiratory symptoms were associated with higher odds of pneumococcal colonization (adjusted OR: 2.1; 95% CI = 1.1-3.8). Pneumococcal carriage among non-institutionalized adults ≥65 years of age was very low. Less than 0.5% of both vaccinated and unvaccinated individuals in our study carried vaccine-type serotypes. Over a decade of PCV vaccination of children likely led to indirect effects in adults. However, given the low vaccine-type carriage rates we observed in an already high PCV13 adult coverage setting, it is difficult to attribute our findings to the direct versus indirect effects of PCV13 on adult carriage.

19 October 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJennifer Milucky
Jennifer Milucky
TPTracy Pondo
Tracy Pondo
CGChristopher J. Gregory
Christopher J. Gregory
DIDanielle Iuliano
Danielle Iuliano
SCSandra S. Chaves
Sandra S. Chaves
TGthe Adult TAC Working Group
the Adult TAC Working Group
Etiology studies of severe acute respiratory infections (SARI) in adults are limited. We studied potential etiologies of SARI among adults in six countries using multi-pathogen diagnostics. We enrolled both adults with SARI (acute respiratory illness onset with fever and cough requiring hospitalization) and asymptomatic adults (adults hospitalized with non-infectious illnesses, non-household members accompanying SARI patients, adults enrolled from outpatient departments, and community members) in each country. Demographics, clinical data, and nasopharyngeal and oropharyngeal specimens were collected from both SARI patients and asymptomatic adults. Specimens were tested for presence of 29 pathogens utilizing the Taqman® Array Card platform. We applied a non-parametric Bayesian regression extension of a partially latent class model approach to estimate proportions of SARI caused by specific pathogens. We enrolled 2,388 SARI patients and 1,135 asymptomatic adults from October 2013 through October 2015. We detected ≥1 pathogen in 76% of SARI patients and 67% of asymptomatic adults. Haemophilus influenzae and Streptococcus pneumoniae were most commonly detected (≥23% of SARI patients and asymptomatic adults). Through modeling, etiology was attributed to a pathogen in most SARI patients (range among countries: 57.3–93.2%); pathogens commonly attributed to SARI etiology included influenza A (14.4–54.4%), influenza B (1.9–19.1%), rhino/enterovirus (1.8–42.6%), and RSV (3.6–14.6%). Use of multi-pathogen diagnostics and modeling enabled attribution of etiology in most adult SARI patients, despite frequent detection of multiple pathogens in the upper respiratory tract. Seasonal flu vaccination and development of RSV vaccine would likely reduce the burden of SARI in these populations.

2 March 2023 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
MSMelisa M. Shah
Melisa M. Shah
KPKadam Patel
Kadam Patel
JMJennifer Milucky
Jennifer Milucky
CTChristopher A. Taylor
Christopher A. Taylor
ARArthur Reingold
Arthur Reingold
TTthe CDC COVID‐NET Surveillance Team
the CDC COVID‐NET Surveillance Team
Background: Bacterial and viral infections can occur with SARS‐CoV‐2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood.Methods: We used the Coronavirus Disease 2019‐Associated Hospitalization Surveillance Network (COVID‐NET), a population‐based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory‐confirmed SARS‐CoV‐2 infection between March 2020 and April 2022. Clinician‐driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non‐SARS‐CoV‐2 endemic coronaviruses.Results: Among 36 490 hospitalized adults with COVID‐19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co‐morbidities, bacterial infections in patients with COVID‐19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing. Staphylococcus aureus and Gram‐negative rods were the most frequently isolated bacterial pathogens. Among hospitalized adults with COVID‐19, 2766 (7.6%) were tested for seven virus groups. A non‐SARS‐CoV‐2 virus was identified in 0.9% of tested patients.Conclusions: Among patients with clinician‐driven testing, 6.0% of adults hospitalized with COVID‐19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.

11 January 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDodi Safari
Dodi Safari
WDWa Ode Dwi Daningrat
Wa Ode Dwi Daningrat
JMJennifer L. Milucky
Jennifer L. Milucky
MKMiftahuddin Majid Khoeri
Miftahuddin Majid Khoeri
WPWisiva Tofriska Paramaiswari
Wisiva Tofriska Paramaiswari
TPTamara Pilishvili
Tamara Pilishvili
Pneumococcal conjugate vaccines (PCVs) prevent nasopharyngeal colonization with vaccine serotypes of Streptococcus pneumoniae, leading to reduced transmission of pneumococci and stronger population-level impact of PCVs. In 2017 we conducted a cross-sectional pneumococcal carriage study in Indonesia among children aged <5 years before 13-valent PCV (PCV13) introduction. Nasopharyngeal swabs were collected during visits to community integrated health service posts at one peri-urban and one rural study site. Specimens were analyzed by culture, and isolates were serotyped using sequential multiplex polymerase chain and Quellung reaction. Antibiotic susceptibility was performed by broth microdilution method. We enrolled 1,007 children in Gunungkidul District, Yogyakarta (peri-urban) and 815 in Southwest Sumba, East Nusa Tenggara (rural). Pneumococcal carriage prevalence was 30.9% in Gunungkidul and 87.6% in Southwest Sumba (combined: 56.3%). PCV13 serotypes (VT) carriage was 15.0% in Gunungkidul and 52.6% in Southwest Sumba (combined: 31.8%). Among pneumococcal isolates identified, the most common VT were 6B (16.4%), 19F (15.8%), and 3 (4.6%) in Gunungkidul (N = 323) and 6B (17.6%), 19F (11.0%), and 23F (9.3%) in Southwest Sumba (N = 784). Factors associated with pneumococcal carriage were age (1–2 years adjusted odds ratio (aOR) 1.9, 95% CI 1.4–2.5; 3–4 years aOR 1.5, 95% CI 1.1–2.1; reference <1 year), other children <5 years old in the household (aOR 1.5, 95% CI 1.1–2.0), and presence of ≥1 respiratory illness symptom (aOR 1.8, 95% CI 1.4–2.2). Overall, 61.5% of the pneumococcal isolates were non-susceptible to ≥1 antibiotic class and 13.2% were multi-drug non-susceptible (MDNS) (non-susceptible to ≥3 classes of antibiotics). Among 602 VT isolates, 73.9% were non-susceptible and 19.9% were MDNS. These findings are critical to establish a pre-PCV13 carriage prevalence and demonstrate the complexity in evaluating the impact of PCV13 introduction in Indonesia given the wide variability in the carriage prevalence as shown by the two study sites.

1 July 2021 in Vaccine
Verified
Journal Article
Closed access
MKMiwako Kobayashi
Miwako Kobayashi
AAAbass Abdul-Karim
Abass Abdul-Karim
JMJennifer L. Milucky
Jennifer L. Milucky
AZAdam Zakariah
Adam Zakariah
ALAndrew J. Leidner
Andrew J. Leidner
FLFernanda C. Lessa
Fernanda C. Lessa